The conversation on sustainable packaging has now reached the heart of the pharmaceutical industry. Otrivin, Haleon’s leading nasal spray brand, has introduced a new dispensing pump made with 52% bio-based materials, developed in collaboration with Aptar Pharma. While the innovation may appear incremental, its symbolic and regulatory weight makes it a noteworthy case for the healthcare sector.
For years, sustainability in packaging has mainly focused on food and cosmetics, where regulations are strict but allow more room for experimentation. Pharmaceuticals, by contrast, have long remained on the sidelines of the debate. Here, packaging is not just a matter of marketing or logistics: it is classified as a component critical to product safety, stability, and efficacy. Any change must be validated through demanding approval processes.
This is why the Otrivin launch stands out. By integrating bio-based content into a widely used over-the-counter product, Haleon and Aptar Pharma are showing that compliance with healthcare standards can go hand in hand with climate-conscious innovation. The move also anticipates the tightening of European legislation. The upcoming Packaging and Packaging Waste Regulation (PPWR) will require significant reductions in virgin plastics and a transition to recyclable or renewable materials. For pharmaceutical players, often exempt from the fastest waves of regulatory change, this step signals the need to adapt sooner rather than later.
Beyond regulation, there is another driver that cannot be underestimated: consumer perception. Patients are increasingly aware of the environmental footprint of the products they use, and expectations for “green” solutions now extend to healthcare packaging. Research indicates that a growing share of consumers actively prefer brands with visible sustainability commitments. For a product like Otrivin nasal spray (used daily by millions and sold in virtually every pharmacy) introducing a bio-based pump means sending a message of trust and responsibility. Sustainability is no longer a “nice-to-have”; it is becoming part of brand credibility, even in healthcare.
Of course, a pump containing 52% bio-based material is not the final goal. The long-term challenge lies in scaling bio-based content further, ensuring recyclability of complex dispensing systems, and rethinking the overall material mix. But as a first step, this launch demonstrates the feasibility of sustainable innovation in a highly regulated sector.
In the broader perspective, Otrivin’s initiative is more than a product update. It reflects a cultural shift: the pharma industry is beginning to align with the same pressures, regulatory and social, that are reshaping packaging across all sectors. If healthcare packaging can embrace sustainability without compromising safety, the ripple effect could be profound.
